- Home
- ONCY vs XGN Comparison
ONCY vs XGN Comparison
Compare ONCY & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCY
- XGN
- Stock Information
- Founded
- ONCY 1998
- XGN 2002
- Country
- ONCY Canada
- XGN United States
- Employees
- ONCY N/A
- XGN N/A
- Industry
- ONCY Pharmaceuticals and Biotechnology
- XGN Medical Specialities
- Sector
- ONCY Health Care
- XGN Health Care
- Exchange
- ONCY Nasdaq
- XGN Nasdaq
- Market Cap
- ONCY 56.2M
- XGN 72.3M
- IPO Year
- ONCY 1999
- XGN 2019
- Fundamental
- Price
- ONCY $0.70
- XGN $5.01
- Analyst Decision
- ONCY Strong Buy
- XGN Strong Buy
- Analyst Count
- ONCY 2
- XGN 2
- Target Price
- ONCY $4.00
- XGN $7.50
- AVG Volume (30 Days)
- ONCY 2.6M
- XGN 160.4K
- Earning Date
- ONCY 03-06-2025
- XGN 03-17-2025
- Dividend Yield
- ONCY N/A
- XGN N/A
- EPS Growth
- ONCY N/A
- XGN N/A
- EPS
- ONCY N/A
- XGN N/A
- Revenue
- ONCY N/A
- XGN $55,751,000.00
- Revenue This Year
- ONCY N/A
- XGN $6.81
- Revenue Next Year
- ONCY N/A
- XGN $17.72
- P/E Ratio
- ONCY N/A
- XGN N/A
- Revenue Growth
- ONCY N/A
- XGN 8.00
- 52 Week Low
- ONCY $0.67
- XGN $1.30
- 52 Week High
- ONCY $1.53
- XGN $6.22
- Technical
- Relative Strength Index (RSI)
- ONCY 32.48
- XGN 48.60
- Support Level
- ONCY $0.67
- XGN $3.87
- Resistance Level
- ONCY $0.90
- XGN $4.26
- Average True Range (ATR)
- ONCY 0.05
- XGN 0.35
- MACD
- ONCY -0.01
- XGN 0.06
- Stochastic Oscillator
- ONCY 8.70
- XGN 74.67
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.